BioMedWire Stocks

Armistice Capital LLC Cuts Stake in Shopify by 59%

Last week, a well-known hedge fund based in New York significantly reduced its stake in Shopify Inc. Shopify is a multinational, e-commerce company headquartered in Ontario, Canada. The company offers e-commerce solutions for micro, small and large businesses, allowing them to sell their services and products online without any hitches.

The hedge fund in question, Armistice Capital LLC, is a global value-oriented and event-driven hedge fund that focuses primarily on the healthcare and consumer sectors. Armistice recently filed a report with the Securities & Exchange Commission reducing its position in Shopify by 59%. It is reported that the institutional investor is left with 256,000 shares in the e-commerce company, having already sold 369,000 shares in 2020.

This news comes as a surprise to many experts in the industry, especially since Shopify experienced massive growth at the start of the pandemic as a result of a considerable increase in online shopping.

Despite Shopify showing promise as its profitability and popularity continues to grow, Armistice Capital has made the decision to reevaluate its investment strategy, with its recent move suggesting that its view of the e-commerce company’s potential for financial gain may have shifted.

Armistice has yet to clarify the factors that may have contributed to its change of heart with regard to Shopify. However, speculation points to increased competition from other companies as well as market volatility, with some arguing that this may discourage investors who saw potential in the e-commerce giant.

While it remains unclear whether this decision by Armistice Capital will cause ripple effects throughout the marketplace, the move to reduce its stake has conveyed a message of uncertainty when it comes to the future of the e-commerce industry.

This comes as another globally renowned institutional investment company, Baillie Gifford & Co, increases its stake in the company. During the fourth quarter alone, Baillie Gifford & Co. bought an additional 12.3% stake in Shopify, acquiring almost 8 million shares for a little more than $2.5 million. Additionally, Sand Capital Management LLC, Franklin Resources Inc. and Vanguard Group Inc. have also increased their position in the multinational e-commerce company in the last three quarters.

Furthermore, different research reports conducted by service providers and financial analysts such as the Royal Bank of Canada and Bloomberg.com also show investors’ bullish sentiments on Shopify’s price from now onwards.

Data from Jefferies Financial Group shows the company raised its price objective on Shopify’s shares to $65 from $44, while the Royal Bank of Canada also increased its price objective to $75 from $65.

A number of companies such as NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW) have dipped a foot in the healthcare ecommerce space, and such significant interest could result in major innovations within that space during the coming years.

NOTE TO INVESTORS: The latest news and updates relating to NextPlat Corp. (NASDAQ: NXPL) are available in the company’s newsroom at https://ibn.fm/NXPL

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

The Global Market for Brain Tumor Treatments Will Reach $7.15 Billion by 2035

The global market for brain tumor treatments is experiencing significant transformation powered by advances in…

1 day ago

New Blood Test Shows Potential in Revolutionizing Early Parkinson’s Detection

A team of researchers has developed a “cost-effective” and simple blood test with the potential…

3 days ago

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible…

3 days ago

Nutriband Inc. (NASDAQ: NTRB) Leading the Way in Transformative Partnerships Formed in Growing Pharma Sector

Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of…

4 days ago

Adageis Helps Medical Providers Track and Build Revenue Through Efficient Application of Value-Based Care

Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to…

1 week ago

Blocking an Enzyme in Melanoma Patients Could Overcome Resistance to Immunotherapy

Approximately 65% of patients diagnosed with melanoma are unresponsive to immunotherapy. New research suggests that…

1 week ago